Spectrum gets FDA plant approval; Hovione and Solvias pair up on co-crystals; Public Citizen wants compounders inspected;

> Spectrum Pharmaceuticals' new manufacturing site has received FDA approval for the production of Fusilev injection for use in advanced metastatic colorectal cancer patients. Item

> Hovione has buddied up with Solvias to combine formulation capabilities and crystal design for manufacturing pharmaceutical co-crystals. Release

> The USP will delay new elemental impurities standards to get them synced up with those in ICH Q3D. Item

> Watchdog group Public Citizen has requested that the FDA reinspect more than a dozen specialty pharmacies with prior records of violations in light of the lethal meningitis outbreak tied to drugs manufactured by New England Compounding Center. Story

And Finally... Johnson & Johnson ($JNJ) says it is making its HIV drug Prezista available to generics makers in Africa and developing countries. Story

Suggested Articles

Neopharma, which has been buying and building plants for several years, is buying a sterile injectables plant and assets in Japan from India’s Lupin. 

Already knocked by the FDA four times this year, Dr. Reddy’s now has a fifth Form 483 to dwell on. This time it’s at a plant with a history of faults.

In a warning letter, the FDA details how a Chinese OTC drugmaker handed over documents faked just for the agency's inspection—and admitted it.